International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group最新文献

{"title":"The rationale for monitoring both skin and invasive temperatures in locoregional recurrent breast cancer patients treated with postoperative re-irradiation and superficial microwave hyperthermia exceeding 1 cm target depth.","authors":"Johannes Crezee, C Paola Tello Valverde, M Willemijn Kolff, H J G Desirée van den Bongard, Ben J Slotman, Akke Bakker, H Petra Kok","doi":"10.1080/02656736.2026.2732510","DOIUrl":"https://doi.org/10.1080/02656736.2026.2732510","url":null,"abstract":"<p><strong>Background: </strong>Thermoradiotherapy at 40-43 °C is an effective treatment for locoregional recurrent (LRR) breast cancer patients. During hyperthermia temperature monitoring is often limited to skin temperatures, but their predictive value for achieving locoregional tumor control (LRC) remains unclear for tumor depths ≥1cm. This study compared predictive value of skin versus invasive intratarget temperatures.</p><p><strong>Methods: </strong>We reported earlier the thermal dose-effect relationship in 112 patients with LRR breast cancer treated in 2010-2017 with postoperative re-irradiation (8 × 4 Gy/23 × 2 Gy) and 4-5 weekly hyperthermia sessions with 434 MHz microwave applicators. Bolus cooling enabled semi-superficial target depths (1-4 cm), thermocouple thermometry monitored both skin and intratarget temperatures. The present study analyzes relationships between LRC and average skin and intratarget median temperature T₅₀ and best session with highest median thermal dose CEM43T50 (cumulative equivalent minutes at 43 °C). Pearson correlation coefficient analysis evaluated correlation between intratarget and skin temperature parameters.</p><p><strong>Results: </strong>Average median skin and invasive temperatures were T₅₀ = 40.6 °C (Interquartile Range IQR 40.3-40.8) and T₅₀ = 40.7 °C (IQR 40.0-41.3), respectively, without association between skin and intratarget temperatures. Median CEM43T50 for skin and intratarget were 2.8 (IQR 2.0-4.3) and 7.2 min (IQR 3.4-15.9) in the best hyperthermia session, respectively. Twenty-four patients developed infield recurrences; median time-to-recurrence was 3.4 years (IQR 2.7-4.6 years). Univariate and multivariate analysis showed significant association of intratarget temperature parameters with LRC (<i>p</i> = 0.015; <i>p</i> = 0.021, respectively), but not for skin temperature parameters and LRC (<i>p</i> = 0.131; <i>p</i> = 0.215, respectively).</p><p><strong>Conclusion: </strong>Temperature monitoring using both skin and invasive intratarget measurements is key for ensuring good quality superficial hyperthermia delivery for tumor depths ≥1cm.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2732510"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149122780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cisplatin combined with high-intensity focused ultrasound inhibits endometrial cancer progression by inducing pyroptosis.","authors":"Chuqiang Shu, Pu Zhang, Qi Tian, Ziqing Wan, Guang Li, Chengzhi Li, Zhibiao Wang","doi":"10.1080/02656736.2026.2705285","DOIUrl":"https://doi.org/10.1080/02656736.2026.2705285","url":null,"abstract":"<p><strong>Background: </strong>Cisplatin-based chemotherapy is limited by toxicity and resistance.High-intensity focused ultrasound (HIFU) is a noninvasive ablation technique with potential to enhance chemotherapy efficacy.</p><p><strong>Objective: </strong>To investigate the anti-tumor effects and mechanisms of cisplatin combined with HIFU in endometrial cancer.</p><p><strong>Methods: </strong>Safe cisplatin concentrations and HIFU parameters were screened in HEEpiC-SV40 cells. Proliferation, apoptosis, migration, and invasion of Ishikawa cells were assessed using CCK-8, EdU, colony formation, TUNEL, wound healing, and Transwell assays. Pyroptosis-related markers and PI3K/AKT pathway activity were evaluated by Western blot, qRT-PCR, and ELISA. Therapeutic efficacy was further examined in a nude mouse xenograft model.</p><p><strong>Results: </strong>Cisplatin (5 μg/mL) combined with HIFU (1 MHz, 160 J) was identified as the optimal treatment condition. The combination significantly inhibited Ishikawa cell proliferation, migration, and invasion while promoting pyroptosis. Mechanistically, combined treatment suppressed PI3K/AKT pathway activation and increased pyroptosis-related markers. These effects were reversed by the pyroptosis inhibitor AZL-N. Moreover, PI3K/AKT activation with 740 Y-P attenuated the anti-tumor and pyroptosis-inducing effects of the combination. <i>In vivo</i>, cisplatin combined with HIFU markedly restrained xenograft tumor growth and promoted tumor pyroptosis, whereas 740 Y-P pretreatment counteracted these effects.</p><p><strong>Conclusions: </strong>Cisplatin combined with HIFU suppresses Type I endometrial cancer progression by inhibiting PI3K/AKT signaling and promoting pyroptosis, supporting its potential as a novel combination therapeutic strategy.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2705285"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149066600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy versus photothermal therapy alone for breast cancer xenograft tumors: a meta-analysis.","authors":"Hua-Wei Gao, Zhi-Hong Li, Yan Lu, Yi-Gong Fang, Fang-Fang Shen, Ling-Wei Song, Fang-Zhou Yu","doi":"10.1080/02656736.2026.2699379","DOIUrl":"10.1080/02656736.2026.2699379","url":null,"abstract":"<p><strong>Objective: </strong>To systematically evaluate the efficacy of doxorubicin (DOX)-loaded graphene nanoplatform chemo-photothermal therapy (CPT) compared with photothermal therapy (PTT) alone on relative tumor volume (RTV) in breast cancer xenograft models and to summarize reported secondary safety and translational endpoints.</p><p><strong>Methods: </strong>PubMed, Embase, Web of Science, and Cochrane Library were searched for animal studies published from January 2010 to December 2025 investigating DOX-loaded graphene nanomaterial-mediated CPT in breast cancer xenograft tumors. Hedges' g was used as the effect size measure, and standardized mean differences (SMDs) were pooled using a random-effects model. Heterogeneity, publication bias, subgroup analyses, sensitivity analyses, and qualitatively reported secondary endpoints were assessed.</p><p><strong>Results: </strong>Nine breast cancer xenograft studies were included, involving 46 animals in the CPT group and 46 in the PTT group. The pooled SMD was -2.20 (95% CI: -2.76 to -1.65, <i>p</i> < 0.0001), with negligible heterogeneity (I2 = 0.0%). Subgroup analyses showed no statistically significant differences by cell line, graphene type, or publication period (all <i>p</i> > 0.05). Leave-one-out sensitivity analyses yielded pooled SMDs from -2.09 to -2.37. Funnel plot inspection and Egger's test suggested mild small-study asymmetry, but Trim-and-Fill correction did not change the direction or significance of the result. Secondary endpoint extraction showed limited survival, toxicity, biodistribution, and clearance reporting, supporting short-term tolerability but not definitive clinical translation.</p><p><strong>Conclusion: </strong>DOX-loaded graphene nanoplatform CPT was associated with significantly greater suppression of RTV than PTT alone in breast cancer xenograft models. The evidence supports a robust preclinical antitumor association while highlighting the need for standardized survival, long-term toxicity, biodistribution, and elimination studies before clinical application.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2699379"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148451288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the efficacy of microwave ablation therapy for benign thyroid nodules of different compositions.","authors":"Chaonan Li, Yunhao Luo, Yunjun Liu, Chao Feng, Zhe Song, Jun Luo","doi":"10.1080/02656736.2026.2697484","DOIUrl":"https://doi.org/10.1080/02656736.2026.2697484","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the 2-year nodule volume reduction rate (VRR), recurrence rate, and safety of ultrasound-guided microwave ablation (MWA) for benign thyroid nodules with different compositions, and to identify independent risk factors affecting therapeutic outcomes.</p><p><strong>Methods: </strong>A single-center retrospective cohort study was conducted on 508 benign thyroid nodules (from 462 patients) treated with MWA between January 2018 and December 2023. Nodules were categorized as solid (G1), predominantly solid (G2), or predominantly cystic (G3). VRR, recurrence, and complications were assessed at 1, 3, 6, 12, and 24 months post-ablation. Multivariate regression and Kruskal-Wallis tests were used for statistical analysis.</p><p><strong>Results: </strong>A significant interaction between follow-up duration and nodule composition was observed for VRR (<i>p</i> < 0.001). At 24 months, the overall median VRR was 86.02%, with G3 (92.46%) significantly higher than G1 (84.32%) and G2 (85.55%) (<i>p</i> < 0.001). The 2-year recurrence rate was 2.56% (G1: 3.35%, G3: 0%), and the overall complication rate was 7.48% (G1: 14.50% > G3: 6.36%, <i>p</i> = 0.028). Multivariate analysis identified nodule composition as an independent predictor of VRR (<i>β</i> = 0.783, <i>p</i> < 0.001) and recurrence (OR = 4.21, <i>p</i> = 0.005), while a maximum nodule diameter >60 mm was a recurrence risk factor (OR = 3.87, <i>p</i> = 0.020). Higher ablation parameters in G1 correlated with increased complications (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Ultrasound-guided MWA is effective and safe for benign thyroid nodules, with cyst-dominant nodules demonstrating the best prognosis. Nodule composition is a core determinant of efficacy and recurrence, and higher ablation parameters are associated with increased complication risks.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2697484"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148709399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of breast biopsy markers on magnetic resonance-guided focused ultrasound.","authors":"Samuel I Adams-Tew, Audrey Johnson, Joshua Crockett, Kate E Adams, Dennis L Parker, Nicole Winkler, Allison Payne","doi":"10.1080/02656736.2026.2632351","DOIUrl":"10.1080/02656736.2026.2632351","url":null,"abstract":"<p><strong>Background: </strong>The placement of a biopsy marker at the time of breast biopsy is standard of care to mark the biopsy site and facilitate surgical excision. However, their impact on incisionless treatments like magnetic resonance-guided focused ultrasound remains underexplored. These factors are important considerations for the design and execution of translational research in this field.</p><p><strong>Methods: </strong>Five commercially available markers were evaluated. Magnetic resonance imaging studies characterized artifact size across various treatment planning and monitoring sequences, as well as MR thermometry performance during focused ultrasound heating. Hydrophone scans collected acoustic field measurements in the presence of biopsy markers. Ablated volume in <i>ex vivo</i> tissue with and without markers present was estimated using measurements from thermal dose and gross tissue processing.</p><p><strong>Results: </strong>Substantial variability in artifact size and shape was observed across the markers. Thermometry showed both imaging and measurement artifacts, with off-target sites showing erroneous temperature change measurements of -30 to 100 °C in some cases. Acoustic field measurements revealed shape- and material-dependent distortions when markers were positioned near the ultrasound focus. Ablation experiments showed mixed effects on treatment volumes.</p><p><strong>Conclusion: </strong>The presence of biopsy markers introduces marker-dependent complexities into magnetic resonance-guided focused ultrasound treatment planning and monitoring. Reliable monitoring and energy delivery are achievable when the target is sufficiently far from the marker but become unreliable when the target is close to the marker. Accordingly, the potential impacts of biopsy markers on the safety and efficacy of MR-guided focused ultrasound treatments should be considered carefully.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2632351"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13074824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147274257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer.","authors":"Andrew S Mikhail, Sandeep Gurram, Vladimir A Valera, Dieter Haemmerich, Nikhil Gopal, Ivane Bakhutashvili, William Richardson, Cody J Peer, Matthew F Starost, Charles Hesswani, Keith T Schmidt, William D Figg, John W Karanian, William F Pritchard, Bradford J Wood","doi":"10.1080/02656736.2026.2615462","DOIUrl":"10.1080/02656736.2026.2615462","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the safety and pharmacokinetics of lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox^®) combined with mitomycin C (MMC) hyperthermic intravesical chemotherapy (HIVEC) as a potential treatment for non-muscle invasive bladder cancer.</p><p><strong>Materials and methods: </strong>Four healthy swine received a 30-minute intravenous infusion of LTLD in combination with HIVEC, consisting of one hour of warm MMC bladder recirculation. Full-thickness bladder wall specimens were surgically resected within 30 min of HIVEC completion for histologic analysis and assessment of doxorubicin (DOX) intrinsic fluorescence in cross sections. DOX and MMC concentrations were also measured in bladder specimens and in serial blood samples up to 4 h by LC/MS. Swine were monitored for 28 days for signs of toxicity and were weighed weekly. Complete blood counts were performed at 4 h and 28 days. Cystoscopy was performed at 28 days, and bladder tissue was collected for histology and quantification of drug concentrations.</p><p><strong>Results: </strong>Mean DOX concentration in the bladder wall 30 min after treatment was 13.6 ± 4.67 µg/g, and DOX fluorescence was visible in all layers. Plasma DOX C_max and AUC_0-∞ were 16.4 ± 3.46 µg/mL and 23.2 ± 5.50 µg/mL · h, respectively. MMC was not detected in the bladder wall or blood above the lower limit of detection (20 ng/mL). The treatment was well tolerated, with no treatment-related adverse events and no weight loss during the 28-day observation. On day 28, cystoscopy demonstrated normal-appearing bladder lumen, and some vacuolated cells were observed on bladder wall histology.</p><p><strong>Conclusions: </strong>Intravenous LTLD combined with MMC HIVEC was feasible and well tolerated in swine.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2615462"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13532398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146115014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modulated electro-hyperthermia enhances tumor cell susceptibility to γδ T cell-mediated cytotoxicity and tumor infiltration in NOD/SCID xenograft models.","authors":"Yi-Ching Chen, Chiao-Hsu Ke, Yu-Kang Chang, Min-Che Tung, Keng-Li Lan, Yuk-Wah Tsang, Heng-Jui Chang, Gin-Hao Hu, Long-Sheng Lu, Stephen Wan Leung, Pei-Wei Shueng, Shih-Kai Hung, Yee Chao, Yu-Shan Wang, Yu-Chi Chiu","doi":"10.1080/02656736.2026.2665691","DOIUrl":"10.1080/02656736.2026.2665691","url":null,"abstract":"<p><strong>Background: </strong>Numerous studies have reported γδ T cell therapy as a promising immunotherapeutic strategy for cancer treatment; however, its efficacy remains limited by insufficient tumor infiltration and target cell susceptibility. Modulated electro-hyperthermia (mEHT) is a loco-regional hyperthermia modality that selectively delivers amplitude-modulated radiofrequency energy to tumor tissues and may induce both thermal and non-thermal biological effects.</p><p><strong>Methods: </strong>In this study, we investigated whether mEHT could enhance tumor cell susceptibility to γδ T cell-mediated cytotoxicity and promote immune cell infiltration. Human γδ T cells were expanded <i>ex vivo</i> and co-cultured with tumor cells pretreated with mEHT or conventional water bath heating.</p><p><strong>Results: </strong>mEHT-treated tumor cells exhibited significantly increased susceptibility to γδ T cell-mediated cytotoxicity compared with controls. In HepG2 xenograft-bearing NOD/SCID mice, local mEHT treatment followed by intravenous injection of γδ T cells resulted in significantly suppressed tumor growth and increased intratumoral CD3⁺ T cell infiltration compared with either monotherapy. Each experimental group consisted of six mice.</p><p><strong>Conclusion: </strong>Taken together, these findings suggest that mEHT may enhance tumor cell susceptibility to γδ T cell-mediated cytotoxicity and may facilitate immune cell infiltration. These effects could potentially involve both thermal and non-thermal biological responses induced by mEHT. This study therefore provides proof-of-concept that combining mEHT with γδ T cell-based immunotherapy may be a promising strategy that warrants further mechanistic and translational investigation.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2665691"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148311319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of efficacy and safety of transarterial embolization sequential microwave ablation for hepatic hemangioma.","authors":"Yixuan An, Ningning Lu, Liang Ma, Wenfeng Gao, Ning He, Xiaozhen Yang, Chunwang Yuan","doi":"10.1080/02656736.2026.2701322","DOIUrl":"https://doi.org/10.1080/02656736.2026.2701322","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy and safety of transarterial embolization (TAE) sequential microwave ablation (MWA) for hepatic hemangioma (HH).</p><p><strong>Methods: </strong>This single-center retrospective study included 122 patients with 134 HHs treated from 2013 to 2024. TAE was followed by CT-guided MWA after 3-14 days. Technical efficacy was defined as ≥50% HH volume reduction at 6 months post-ablation. Hemoglobinuria within 24 h after MWA was analyzed as a safety outcome. Correlation analysis was used to avoid simultaneous inclusion of highly correlated tumor burden and ablation-related variables. Tumor volume and ablation time were selected as representative variables. Generalized estimating equation (GEE) logistic regression accounted for within-patient clustering. Receiver operating characteristic (ROC) analysis was exploratory.</p><p><strong>Results: </strong>Technical success and technical efficacy were 100% and 87.3%, respectively. At 6 months after ablation, median maximum diameter decreased from 7.5 to 5.0 cm and median volume from 138.9 to 40.0 cm³ (both <i>p</i> < 0.001). The 30-day complication rate was 52.2%, with no major complications. Hemoglobinuria occurred in 36.6% and resolved within 24 h. In multivariable GEE analysis, ablation time remained associated with hemoglobinuria (OR = 1.096, 95% CI: 1.045-1.149, <i>p</i> < 0.001), whereas tumor volume was not significant. ROC analysis showed good exploratory discrimination for ablation time (AUC = 0.824), with an exploratory cutoff of 28.5 min.</p><p><strong>Conclusions: </strong>TAE sequential MWA effectively reduces HH volume with acceptable safety. Hemoglobinuria was common but transient and had no clear adverse clinical consequences. Ablation time may serve as an exploratory reference for short-term postoperative monitoring.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2701322"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148431912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engineering and characterization of a novel hydrogel-based cancer spheroid system to recapitulate clinical wIRA -hyperthermia treatments.","authors":"Anne-Marie Lüchtenborg, Helmut Piazena, Peter Vaupel, Anca-Ligia Grosu, Andreas R Thomsen, Khairunadwa Jemon","doi":"10.1080/02656736.2026.2719926","DOIUrl":"https://doi.org/10.1080/02656736.2026.2719926","url":null,"abstract":"<p><strong>Background: </strong>Water-filtered infrared-A (wIRA) mild hyperthermia (mHT) combined with radiotherapy can effectively treat superficial tumors. While <i>in vitro</i> models are essential for mechanistic studies, existing approaches mostly rely on monolayer cultures and non-clinical heating. We present a multilayer agarose-based platform enabling clinically relevant wIRA-hyperthermia of 3D-tumor spheroids using a clinical device, reproducing spatial thermal gradients and thermographic feedback control without an external heat source.</p><p><strong>Methods: </strong>We designed a multilayer stack with alternating layers of hemoglobin-agarose chips (2% Hb, 2% talcum) as infrared absorbers, spacers, and microwell chips containing tumor spheroids at 5 and 11 mm depth. Temperature profiles were characterized using thermocouples, and evaluated according to European Society for Hyperthermic Oncology (ESHO) guidelines. We monitored T47D breast cancer spheroid growth by optical scanning for 28 days, and assessed cell death by flow cytometry 48 h post-treatment.</p><p><strong>Results: </strong>The system achieved stable heating from room temperature within 15 ± 8 min, with mean steady-state temperatures of 41.9 ± 0.5 °C (<i>n</i> = 26) and 40.3 ± 0.4 °C at 5 mm and 11 mm depth, respectively. T50 (42.1 ± 0.5 and 40.5 ± 0.3 °C) and T90 values (41.3 ± 0.7 and 39.8 ± 0.7 °C) at these depths met or approached ESHO guidelines. Spheroids at higher temperatures (upper layer) were modestly larger than controls (<i>p</i> < 0.01) at 14 and 28 days; lower temperatures had no effect. mHT did not induce apoptosis or necrosis.</p><p><strong>Conclusion: </strong>The novel model replicates <i>in vivo</i> wIRA temperature profiles in 3D cell culture and supports several downstream analyses. It enables investigation of cellular responses to clinically relevant mHT and provides a technical basis for future translational research.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2719926"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148877227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A clinical study on the efficacy of a novel herbal medicine cocktail in enhancing HIFU treatment for adenomyosis: a pilot randomized controlled trial.","authors":"Ting Lin, Minqi Su, Yan Chen, Junli An, Xueqiong Xu, Xuemei Chen, Gang Wu, Haifeng Wang, Yunfeng Cai, Manling Li, Liuyun Zhou, Jiali Yang, Jingjing Liu, Sangui Wang, Quanlei Wang","doi":"10.1080/02656736.2026.2729542","DOIUrl":"10.1080/02656736.2026.2729542","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical efficacy and potential mechanisms of Traditional Chinese Medicine (TCM) combined with High-Intensity Focused Ultrasound (HIFU) in the treatment of adenomyosis, providing evidence-based support for optimizing clinical treatment strategies.</p><p><strong>Methods: </strong>In this prospective randomized trial, 66 patients were assigned to a control group (HIFU alone) or an observation group (HIFU plus a \"Yiqi Huoxue, Huayu Sanjie\" TCM formula) for 12 weeks. The Visual Analog Scale (VAS) for pain as the primary endpoint, and the Pictorial Blood Loss Assessment Chart (PBAC) for menstrual blood loss, uterine/lesion volumes, and serum carbohydrate antigen 125 (CA125), interleukin-6 (IL-6) as exploratory outcomes were assessed.</p><p><strong>Results: </strong>The results showed that the VAS scores in the observation group were significantly lower than those in the control group after treatment (<i>p</i> < 0.05). The reduction in uterine volume and lesion volume was greater in the observation group compared to the control group (<i>p</i> < 0.05). Serum levels of CA125 and IL-6 decreased more significantly in the observation group (<i>p</i> < 0.05), and no significant abnormalities were observed in safety indicators.</p><p><strong>Conclusion: </strong>The combination of TCM and HIFU treatment suggests a possible benefit in alleviating dysmenorrhea and promoting lesion absorption in patients with adenomyosis. The observed changes in inflammatory status and CA125 levels hint at a potential link with the therapeutic effect. However, these findings should be considered exploratory, and further studies are needed to validate TCM as an adjunctive therapy to HIFU treatment.</p>","PeriodicalId":520653,"journal":{"name":"International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","volume":"43 1","pages":"2729542"},"PeriodicalIF":3.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149043163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}